The efficacy of ustekinumab in the management of perianal fistulizing Crohn’s disease

Key Points

• Ustekinumab leads to significant reduction in fistula formation in patients with Crohn's disease, showing improved symptom management.
• In a cohort of patients, 70% experienced improvement within the first 12 weeks of treatment, highlighting rapid response.
• Observational analysis focused on inflammatory response and fistulizing complications associated with Crohn's disease.
• Findings support the need for more extensive trials to confirm long-term efficacy of ustekinumab in clinical settings.